Northstar Group Inc. cut its holdings in Stryker Co. (NYSE:SYK – Free Report) by 0.6% during the third quarter, Holdings Channel reports. The institutional investor owned 6,265 shares of the medical technology company’s stock after selling 40 shares during the quarter. Northstar Group Inc.’s holdings in Stryker were worth $2,263,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of the business. Centennial Bank AR boosted its stake in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after acquiring an additional 48 shares in the last quarter. Central Pacific Bank Trust Division purchased a new stake in Stryker in the first quarter valued at approximately $39,000. HBW Advisory Services LLC purchased a new position in shares of Stryker in the 3rd quarter worth $42,000. Accent Capital Management LLC acquired a new stake in Stryker during the 4th quarter worth approximately $60,000. Finally, Sachetta LLC grew its stake in Stryker by 16.3% during the second quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after buying an additional 34 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Insider Activity
In other news, Director Ronda E. Stryker sold 190,000 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total value of $61,457,400.00. Following the transaction, the director now directly owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Glenn S. Boehnlein sold 20,000 shares of Stryker stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the transaction, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 190,000 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $323.46, for a total value of $61,457,400.00. Following the sale, the director now owns 3,316,608 shares of the company’s stock, valued at approximately $1,072,790,023.68. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock worth $71,811,372 in the last 90 days. Company insiders own 5.90% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on SYK
Stryker Price Performance
Shares of NYSE SYK traded up $0.87 during mid-day trading on Thursday, reaching $354.83. 42,682 shares of the company traded hands, compared to its average volume of 1,259,450. The firm has a market cap of $135.17 billion, a PE ratio of 40.41, a price-to-earnings-growth ratio of 2.71 and a beta of 0.91. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $374.63. The stock has a fifty day simple moving average of $350.96 and a 200-day simple moving average of $343.00.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period in the previous year, the firm posted $2.54 EPS. The company’s quarterly revenue was up 8.5% on a year-over-year basis. Equities research analysts anticipate that Stryker Co. will post 12 EPS for the current fiscal year.
Stryker Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.90%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Articles
- Five stocks we like better than Stryker
- Why Are Stock Sectors Important to Successful Investing?
- Top 2 Analyst Picks: Stocks Poised for Double-Digit Growth
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These 3 Stocks Are Screaming Oversold: Seize the Opportunity
- Top Biotech Stocks: Exploring Innovation Opportunities
- Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.